AbCellera Biologics Inc. (ABCL): A Bull Case Theory
We came across a bullish thesis on AbCellera Biologics Inc. on topsecretstocks’s Substack. In this article, we will summarize the bulls’ thesis on ABCL.
Abcellera Biologics Inc. (ABCL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 27,525,640 | $94,137,689 | 0.55% | |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 4,878,000 | $16,682,760 | +2% | 0.03% |
| 3. | Driehaus Capital Richard Driehaus | 3,771,999 | $12,900,237 | +119% | 0.09% |
| 4. | Renaissance Technologies Jim Simons | 2,389,229 | $8,171,163 | -29% | 0.01% |
| 5. | Citadel Investment Group Ken Griffin | 1,834,508 | $6,274,017 | +82% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.57 | 50,000 | $178,460.00 | 221,000 | 2025-11-26 | Filing | |
| $2.16 | 343,631 | $742,242.96 | 56,143,640 | 2025-03-11 | Filing | |
| $2.30 | 25,000 | $57,500.00 | 171,000 | 2025-03-10 | Filing | |
| $2.34 | 60,000 | $140,568.00 | 146,000 | 2025-03-06 | Filing | |
| $2.61 | 283,516 | $739,976.76 | 56,086,009 | 2024-08-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.93 | 137,351 | $2,325,352.43 | 128,862 | 2021-09-01 | Filing | |
| $16.95 | 162,649 | $2,756,900.55 | 266,213 | 2021-08-31 | Filing | |
| $25.50 | 100,000 | $2,550,000.00 | 1,003,397 | 2021-06-22 | Filing | |
| $24.03 | 5,598,420 | $134,530,032.60 | 55,604,330 | 2021-06-09 | Filing | |
| $25.50 | 401,580 | $10,240,290.00 | 233,500 | 2021-06-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,361,096 | $45,694,948 | 0.01% | |
| 2. | 7,876,629 | $26,938,071 | 0.01% | |
| 3. | 5,810,985 | $19,873,569 | 0.03% | |
| 4. | 4,344,485 | $14,858,139 | 0% | |
| 5. | 4,105,095 | $14,039,425 | 0.31% |
News See All
What Does Wall Street Think About AbCellera Biologics Inc. (ABCL)?
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best strong buy stocks to invest in under $5. AbCellera Biologics Inc.
10 Best Strong Buy Stocks to Invest In Under $5
On January 28, JoAnne Feeney, Advisors Capital Management partner and portfolio manager, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends. She was of the view that there is...
9 Best Up and Coming Canadian Stocks to Buy
On November 19, IG Wealth Management released its 2026 Market Outlook for Canada.
AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Canadian penny stocks to buy right now. On November 7, Stifel Nicolaus reiterated a Buy rating on AbCellera Biologics Inc.
13 Best Canadian Penny Stocks to Buy Right Now
Penny and small-cap stocks have lagged the overall market amid heightened focus on large caps during the artificial intelligence boom.
Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution?
AbCellera Biologics Inc. (NASDAQ:ABCL) is a must-buy penny stock to buy now. On November 13, at the Stifel 2025 Healthcare Conference, AbCellera Biologics Inc.
11 Must-Buy Penny Stocks to Buy Now
Markets have continued to rally, with the S&P 500 already up by about 15% for the year.
AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to AbCellera's Third Quarter 2025 Business Update Conference Call. My name is Cameron, and I'll facilitate the audio portion of today's interactive broadcast.
AbCellera Biologics Inc. (ABCL): A Bull Case Theory
We came across a bullish thesis on AbCellera Biologics Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares. In this article, we will summarize the bulls’ thesis on ABCL.
Hedge Fund Resource Center